Project Grant R01AI192712
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $501,800 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 4, 2025 through July 31, 2027. This award supports investigator-initiated biomedical research focused on elucidating the molecular structure and mechanisms of the Plasmodium basal complex using cryo-electron tomography (cryo-ET). The research addresses...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $202,055 Project Grant to Harvard T.H. Chan School of Public Health on August 13, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on Plasmodium falciparum apicomplexan amino acid transporter 2 (PfAPIAT2) and its proline transport capability. The research aims to characterize PfAPIAT2's role in proline transport across different...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $810,125 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 9, 2026, for a project period extending through May 31, 2031. This Project Grant funds a comprehensive research evaluation of Plasmodium falciparum infection and naturally acquired immunity (NAI) in samples collected from a Ugandan...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Pennsylvania State University a $247,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective May 1, 2026, through April 30, 2028. This award funds investigator-initiated research to advance understanding of gene expression control mechanisms in Plasmodium parasites during the critical transmission phase from mammalian hosts to mosquito...
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund research by The Trustees of Columbia University in the City of New York to identify and characterize the roles of non-coding RNAs in regulating drug-induced quiescence in Plasmodium falciparum, the parasite that causes malaria. The project aims to uncover novel epigenetic and epitranscriptomic mechanisms that enable...
- Federal Grant Award Summary The Pennsylvania State University received a $196,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 19, 2026, with a completion date of April 30, 2028. The award supports comprehensive research leveraging single-cell RNA sequencing (scRNA-seq) technology to elucidate the molecular mechanisms underlying sexual dimorphism during Plasmodium...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $1.36 million Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 22, 2025, with completion targeted for July 31, 2030. This prospective observational cohort research study examines the impact of early-life malaria and other pathogen...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital of Philadelphia (CHOP) a Project Grant of $187,056 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 7, 2025, with a completion date of June 30, 2030. This research project investigates erythrocyte glycolysis as a novel antimalarial strategy to address the urgent global health threat posed by artemisinin-resistant Plasmodium...
- This Project Grant, awarded on April 13, 2026, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,377,692 in funding to Yale University to conduct research on residual malaria transmission mechanisms in the Peruvian Amazon region through March 31, 2031. The research addresses critical gaps in malaria elimination efforts in Loreto, Peru, which accounts for 95% of all malaria cases in the...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $895,740 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize CD4 T cells targeting liver and blood stage malaria epitopes. The five-year project, awarded February 2, 2026, and concluding January 31, 2031, addresses critical gaps in malaria vaccine development by identifying hundreds of...
PARSEC: PLASMODIUM FALCIPARUM ADAPTIVE RESPONSE TO SICKLE TRAIT ERYTHROCYTES - PROJECT ABSTRACT SICKLE-TRAIT HEMOGLOBIN CONFERS NEAR COMPLETE PROTECTION FROM SEVERE, LIFE-THREATENING PLASMODIUM FALCIPARUM MALARIA IN AFRICAN CHILDREN. THE MECHANISMS OF THIS PROTECTION REMAIN INCOMPLETELY UNDERSTOOD, BUT SEVERAL LINES OF EVIDENCE SUPPORT THE NOTION THAT SICKLE-TRAIT ATTENUATES THE CRITICAL PARASITE PATHOGENIC PHENOTYPE OF CYTOADHERENCE. WE HAVE REPORTED CONSERVED PARASITE TRANSCRIPTIONAL PROGRAMS IN SICKLE-TRAIT RBCS, SUPPORTING A MECHANISM OF THIS ATTENUATED CYTOADHESION THAT IS PRIMARILY POST-TRANSCRIPTIONAL. THIS HYPOTHESIS WAS AUGMENTED BY THE OBSERVATION THAT SOME P. FALCIPARUM PARASITES APPEAR TO HAVE ADAPTED TO INFECT SICKLE-TRAIT RBCS THROUGH MODULATION OF THE GENE PF3D7_1127000, ENCODING A PUTATIVE PROTEIN PHOSPHATASE. IN OUR RECENT PARASITE COMPARATIVE TRANSCRIPTOMIC STUDY IN MALIAN CHILDREN, PF3D7_1127000 WAS THE SINGLE MOST OVEREXPRESSED TRANSCRIPT IN SICKLE-TRAIT CHILDREN AT OVER 30-FOLD. IN AN ORTHOGONAL PARASITE GENOME-WIDE SCREEN, WE OBSERVED THIS GENE AS ENRICHED IN CHILDREN WITH SICKLE-TRAIT CODING MUTATIONS AND IDENTIFIED A STRUCTURAL REARRANGEMENT IN PF3D7_1127000 (AKA "PFSA3"). COLLECTIVELY, THESE DATA SUGGEST THAT A VARIANT LINKED TO OVEREXPRESSION OF PFSA3 IS A KEY PARASITE ADAPTATION TO GROWTH AND DISEASE IN SICKLE-TRAIT. WE WILL BUILD ON THESE CONVERGENT LINES OF EVIDENCE OF PARASITE ADAPTATION TO SICKLE-TRAIT RBCS WITH OUR EXPERIENCE WITH PARASITE EXPERIMENTAL GENETICS AND BIOCHEMISTRY TO INVESTIGATE THE CELLULAR FUNCTIONS OF WILDTYPE AND MUTANT PFSA3 AND ITS ASSOCIATION WITH CLINICAL DISEASE. OUR CENTRAL HYPOTHESIS IS THAT THE ADAPTIVE RESPONSE TO SICKLE-TRAIT RBCS OF PARASITE OVEREXPRESSION OF MUTANT PFSA3 NULLIFIES THE PROTECTION AGAINST CLINICAL DISEASE CONFERRED BY SICKLE- TRAIT. WE WILL TEST THIS HYPOTHESIS BY ENGINEERING TRANSGENIC PARASITES LINES EXPRESSING WILDTYPE AND MUTANT PFSA3 AND UNDERSTANDING THE NATIVE FUNCTIONS OF THE PROTEIN, ITS INTERACTING PARTNERS WITHIN THE PARASITE AND HOST CELL, AND THE EFFECTS OF PFSA3 EXPRESSION ON PATHOGENIC PARASITE PHENOTYPES, INVESTIGATE PFSA3 VARIATION IN A MOLECULAR EPIDEMIOLOGIC STUDY IN WESTERN KENYA, AND CHARACTERIZE THE BIOCHEMICAL ACTIVITY AND STRUCTURE OF PFSA3. THIS PROJECT BUILDS ON CONVERGENT LINES OF GENOMIC AND FUNCTIONAL GENOMIC EVIDENCE THAT IMPLICATE PFSA3 VARIATION IN ADAPTATION TO SICKLE-TRAIT RBCS. WITH OUR COMPLEMENTARY EXPERTISE IN PARASITE PATHOGENESIS, EXPERIMENTAL GENETICS, BIOCHEMISTRY, AND GENOMICS, WE WILL CHARACTERIZE THE NATIVE FUNCTION OF PFSA3 AND THE MECHANISMS BY WHICH IT MEDIATES PARASITE PHENOTYPES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $788.4k | 6/9/26 |